Share on

Global Stem Cell Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Treatment Mode, Cell Type, Technology and Region - Industry Forecast (2023 to 2028)

Published: March, 2023
ID: 1022
Pages: 181
Formats: report pdf report excel report power bi report ppt

Global Stem Cell Market Size (2023 to 2028)

The global stem cell market is estimated to be worth USD 32633 million by 2028 and USD 18173 million in 2023, growing at a CAGR of 12.42% during the forecast period. The market is to increase because of the extensive research and development, which is gaining significant importance.

Global Stem Cell Market Share Insights:

  • Based on treatment mode, the allogenic segment had 60.8% of the global market share in 2022.
  • Based on cell type, the adult stem cells segment accounted for 79.8% of the global market share in 2022.
  • Based on technology, the cell acquisition segment held 34.9% of the worldwide market share in 2022.
  • Based on region, North America captured 44.6% of the worldwide market share in 2022.

In multicellular organisms, stem cells have a unique ability to regenerate into a specific cell to form different tissues in the body. These cells can work as a replacement in place of damaged tissue cells and have full applications in healthcare and as a result, stem cells have been accepted throughout the world. Regenerative medicine is possibly the most important use of stem cells and other essential areas comprise cardiology, neurology, orthopedics, hematology and oncology. Drug discovery is another application where stem cells have been increasingly used. Stem cells are used as a research tool by researchers in vitro studies to deeply understand the role of various organs and the development of diseases. Stem cell therapy has shown significant potential to treat cancer successfully.

Impact of COVID-19 on the global stem cell market:

The COVID-19 pandemic has given both setbacks and opportunities to the global stem cell market. On one side, the COVID-19 pandemic has caused severe disruption in the R&D and clinical trials that involve stem cell therapies and slowed down the pace of research and development in the field. The disruptions in the global supply chains caused by the COVID-19 pandemic resulted in the shortage of materials and equipment required for R&D and manufacturing that have a connection with stem cells and impacted the market growth negatively. On the other hand, the COVID-19 pandemic has boosted the demand for stem cell therapies. During the COVID-19 pandemic, stem cell therapies have been increasingly used for the treatment of acute respiratory distress syndrome (ARDS) caused by COVID-19. Several governments worldwide have come forward and supported the R&D of stem cells to address the challenges posed by the COVID-19 pandemic and favored the market growth during the COVID-19 pandemic term. The usage of telemedicine skyrocketed during the COVID-19 pandemic and several patients worldwide have used the telemedicine platforms to avail healthcare services and get stem cell therapies remotely. Such factors have offered opportunities to the market participants of the stem cell market during the COVID-19 pandemic.

MARKET DRIVERS:

The growing usage of stem cells in cancer treatment primarily drives the global stem cell market growth. The cancer patient population is on the rise worldwide and is expected to fuel in the coming years. WHO says cancer is the second leading cause of death globally and caused an estimated 9.6 million deaths in 2018. The American Cancer Society predicts that there were an estimated 1.9 million new cancer cases in the U.S. were recorded in 2022. The usage of stem cells in cancer treatments has seen a tremendous spike in recent years and this trend is expected to continue in the coming years as stem cells hold great promise to treat cancer. Considering the potential of stem cells such as regenerating damaged tissues and replacing cancerous cells, the demand for stem cells has been increasing steadily over the last few years.

The growing number of R&D activities related to stem cells further fuels the market’s growth rate. The potential that stem cells hold in treating various diseases has been recognized in recent years and several pharmaceutical companies have been conducting numerous R&D activities to explore the possibilities of stem cells and this trend is likely to continue during the forecast period and contribute to the market growth. For Instance, somatic stem cell therapy or bone marrow transplant is a procedure used to treat leukemia (blood cancer) as bone marrow has many stem cells.

The growing aging population worldwide is another major factor boosting the growth rate of the stem cell market. The aging population is on the rise worldwide and as per the estimates of the United Nations (UN), 1 in every 6 people is predicted to be aged above 65 years by 2050 and the total population above 65 years will reach 1.5 billion by 2050. People are much more likely to experience age-related diseases and conditions such as arthritis, cardiovascular diseases, and neurodegenerative disorders with growing age. Stem cell therapies have the ability to treat these conditions by regenerating damaged tissues and organs and this awareness among the healthcare professionals and patient population has increased notably in recent years and boosted the demand levels for stem cells. The regenerative capacity of a human body gradually decreases with growing age and in such situations, stem cell therapies can be used to address age-related health issues such as age-related macular degeneration, osteoporosis and Alzheimer's disease. People who are aged have higher chances of organ failure and require organ transplantation. The world is currently facing a severe shortage of organ donors and some healthcare organizations have been using stem cell-based therapies for organ regeneration as stem cells hold the ability to generate new tissues and organs that can eliminate the need for organ transplantation.

The growing investments by the governments and market participants for the R&D of stem cells, increasing technological advancements, rising awareness regarding the potential benefits of stem cells among healthcare professionals and increasing number of collaborations between the market participants and academic institutions to explore the possibilities of stem cells contribute to the market’s growth rate. The favorable regulations and initiatives by the governments for stem cells, rising demand for regenerative medicine, growing patient population suffering from orthopedic diseases, rising adoption of personalized medicine and growing use of stem cells in drug discovery and development further support the stem cell market growth. The rising demand for stem cell banking services, growing adoption of stem cell therapies in developing countries, increasing number of stem cell clinical trials, technological advancements in stem cell processing and preservation, rising use of stem cells in tissue engineering and growing demand for stem cell-based therapies in veterinary medicine are anticipated to fuel the growth rate of the stem cell market during the forecast period.

MARKET RESTRAINTS:

Ethical and legal concerns especially with embryonic stem cells associated with stem cell research and therapies and high costs associated with stem cell therapies majorly hamper the market growth. Lack of standardization in stem cell research and therapy and limited availability of stem cells further hinder market growth. Unfavorable reimbursement policies for stem cell therapies in some countries, stringent regulatory environment for stem cell research and therapy in some countries, safety and efficacy issues of stem cell therapy and the competition from alternative therapies such as gene therapy and immunotherapy further impede the market growth.

REPORT COVERAGE:

REPORT METRIC

DETAILS

Market Size Available

2022 to 2028

Base Year

2022

Forecast Period

2023 to 2028

Segments Analysed

By Treatment Mode, Cell Type, Technology Segment, and Region

Various analyses covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa

 

This research report on the global stem cell market has been segmented and sub-segmented based on treatment mode, cell type, technology segment, and region.

Stem Cell Market - By Treatment Mode:

  • Allogeneic
  • Autologous

Based on treatment mode, the allogeneic segment had the largest share of the global market in 2022 and the segmental domination is expected to continue during the forecast period. The advancements in stem cell research such as effective methods of harvesting, processing and storing allogeneic stem cells, the shortage of donor stem cells and the rising demand for regenerative medicine boost segmental growth. The rising support and funding from several governments for stem cell research and therapy and the increasing number of regulatory approvals for allogeneic stem cell therapy further drive the segmental growth.

On the other hand, the autologous segment is predicted to register a promising CAGR in the coming years due to factors such as the growing usage of autologous stem cell therapy for chronic disease patient population and rising awareness among the patient population regarding the benefits of autologous stem cell therapy.

Stem Cell Market - By Cell Type:

  • Adult Stem Cells
  • Induced Pluripotent Stem Cells
  • Human Embryonic Stem Cells
  • Others

Based on the cell type, the adult stem cell segment held the leading share of the global market in 2022 and is expected to showcase a healthy CAGR during the forecast period. The growing prevalence of chronic diseases, increasing geriatric population worldwide and rising emphasis on research and development of new therapies based on adult stem cells majorly propel the segmental growth.

The induced pluripotent stem cells segment accounted for the second largest share of the worldwide market in 2022 and grow at the highest CAGR during the forecast period. The rising demand for personalized medicine, the increasing incidence of chronic diseases, the growing focus on research and development of new therapies based on iPSCs and the increasing availability of funding for stem cell research primarily contribute to the segmental growth.

The human embryonic stem cell segment is anticipated to register a steady CAGR during the forecast period owing to the rising emphasis on research and development of new therapies based on hESCs and the growing demand for organ transplantation.

Stem Cell Market - By Technology:

  • Cell Acquisition
  • Cell Production
  • Cryopreservation
  • Other Sub-Segments

Based on technology, the cell acquisition segment had the leading share of the global market in 2022 and is expected to witness notable growth during the forecast period. The growth of the segment is majorly driven by the growing prevalence of chronic diseases, the increasing geriatric population, the rising demand for stem cell therapies and the technological advancements in stem cell isolation and collection techniques.

The cell production segment is a lucrative segment is expected to register the fastest CAGR during the forecast period due to factors such as the growing demand for regenerative medicine, the rising focus on personalized medicine, the development of new stem cell-based therapies and the increasing availability of funding for stem cell research.

The cryopreservation segment is estimated to showcase steady growth during the forecast period. Factors such as the rising demand for stem cell banking, the increasing focus on regenerative medicine, the development of new therapies based on stem cells and technological advancements in cryopreservation techniques majorly support the segmental growth.

Stem Cell Market - By Region:

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • The Middle East and Africa

Geographically, the North American stem cell market held the largest share of the worldwide market in 2022 and the domination of the North American region in the worldwide market is expected to continue throughout the forecast period. The growing prevalence of chronic diseases, rising geriatric population and the growing demand for regenerative medicine in North America majorly propel the North American market growth. The presence of established healthcare infrastructure, technological advancements and favorable government initiatives further contribute to the growth rate of the North American market. The increasing availability of funding for stem cell research, high disposable income, growing healthcare expenditure, increasing number of partnerships and collaborations between industry players and research institutions and growing demand for stem cell-based therapies for the treatment of chronic diseases are anticipated to boost the growth rate of the North American market growth during the forecast period. The National Institute of Health (NIH) has been offering substantial funding support for stem cell research in the U.S. since 2016. The U.S. held the major share of the North American market followed by Canada in 2022 and the same trend is expected to continue throughout the forecast period. Factors such as the growing demand for regenerative medicine and the presence of well-established research and academic institutions majorly drive the U.S. market growth. California is one of the states to watch out for stem cell research. The California Institute for Regenerative Medicine (CIRM) funds stem cell research and clinical trials activities in California.

Europe captured a substantial share of the global market in 2022 and is expected to grow promisingly during the forecast period. The presence of several stem cell research centers and academic institutions, a rising emphasis on regenerative medicine and tissue engineering, a favorable regulatory environment and supportive government initiatives primarily drive the growth of the European stem cell market. The European Union (EU) funded the Innovative Medicines Initiative (IMI) to support the research around stem cells and regenerative medicine in 2020. An increasing number of investments by private organizations in the stem cell industry of Europe, growing awareness and acceptance of stem cell therapy among patients and the rising prevalence of chronic diseases and the aging population further boost the growth rate of the European market. Germany occupied the major share of the European market in 2022 and the German market is expected to grow at a notable CAGR during the forecast period owing to factors such as the presence of well-established research and academic institutions and a supportive regulatory environment in Germany.

However, the APAC stem cell market is expected to grow at the fastest CAGR during the forecast period. The growth of the APAC market is primarily driven by factors such as the rapidly growing biotech and pharmaceutical industry, rising patient pool and increasing demand for stem cell-based therapies, favorable government policies and supportive regulatory environment for stem cell research. The large and diverse population base that provides a wide range of stem cell sources for research and therapy, growing investments in stem cell research and development by both governmental and private organizations, advancements in healthcare infrastructure and increasing healthcare expenditure further promote the growth rate of the APAC market. Japan captured the major share of the APAC market in 2022. The Japanese market is also predicted to register promising growth during the forecast period owing to factors such as the presence of a well-developed healthcare system, favorable regulatory environment, and government support for stem cell research. The Chinese stem cell market accounted for a considerable share of the APAC market in 2022 due to the growing number of clinical trials for stem cell-based therapies. The Indian stem cell market is estimated to register a lucrative CAGR during the forecast period owing to the presence of several companies and research institutions engaged in stem cell research and therapy. South Korea is projected to hold a considerable share of the APAC market during the forecast period.

The Latin American stem cell market is an emerging regional market for stem cells and is predicted to grow at a healthy CAGR during the forecast period due to the growing prevalence of chronic diseases, rising emphasis on regenerative medicine and stem cell therapy, growing healthcare expenditure, improving healthcare infrastructure, favorable regulatory environment and supportive government initiatives for stem cell research and growing awareness and acceptance of stem cell therapy among patients. Brazil and Mexico accounted for the major share of the Latin American market in 2022.

The stem cell market in the Middle East and Africa is forecasted to grow at a steady CAGR during the forecast period. The growing focus on stem cell therapy for the treatment of genetic disorders and rare diseases and rising awareness and acceptance of stem cell therapy among patients majorly boosts regional market growth. Israel and South Africa are predicted to account for the major share of the MEA market during the forecast period.

KEY MARKET PARTICIPANTS:

Some of the notable companies that are profiled in the global stem cell market are Athersys, StemCells, Inc., Cryo Cell International, Geron Corporation, Mesoblast Ltd., Aastrom Biosciences, Inc., Celgene Corporation, Invitrogen, and Cytori Therapeutics Inc.

RECENT MARKET DEVELOPMENTS:

  • Research on mesenchymal stem cells was carried out in 2019 by research professionals at the University of Freiberg.
  • Mesoblast Company collaborates with Grunenthal Inc. to develop innovative cell therapy for treating chronic low back pain. Grunanthal acquired rights from Mesoblast to commercialize MPC-06-ID in Latin America and Europe.

Please wait. . . . Your request is being processed

FAQ's

What is the projected value of global stem cell market by 2028?

As per our report, the global stem cell market size is predicted to be worth USD 32633 million by 2028.

What is the growth rate of the stem cell market?

For the coming period of 2023 to 2028, the global stem cell market is expected to grow at a CAGR of 12.42%

Which segment by treatment mode is expected to play leading role in stem cell market?

Based on treatment mode, the allogeneic therapy segment is predicted to play a major role in the global stem cell market.

Who are the major players are in the global stem cell market?

Athersys, StemCells, Inc., Cryo Cell International, Geron Corporation, Mesoblast Ltd., Aastrom Biosciences, Inc., Celgene Corporation, Invitrogen, and Cytori Therapeutics Inc. are some of the notable companies in the global stem cell market. 

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM

Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!

REACH OUT TO US

Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us: sales@marketdataforecast.com

Click for Request Sample